Triastek Raises Series C+ Led by Johnson & Johnson Innovation – JJDC

Triastek Secures Series C+ Funding Led by Johnson & Johnson Innovation – JJDC

Triastek, a Nanjing-based pharmaceutical technology company, has raised a Series C+ round led by Johnson & Johnson Innovation – JJDC, Inc. The funding date is October 9, 2026. The round type is Series C+. The funding amount was not disclosed. The currency is CNY.

What Triastek Does

Triastek is a global leader in 3D-printed pharmaceuticals. The company uses its proprietary Melt Extrusion Deposition (MED) platform to design and continuously manufacture novel oral drug products. It is the only company in China holding a production license for 3D-printed drugs and has secured multiple FDA IND clearances.

Its newer strategic focus is oral peptides, delivered via its 3DuS-OM platform. A Shanghai international R&D and production center supports clinical and global commercialization.

The Investor

Johnson & Johnson Innovation – JJDC, Inc. led the round. No other investors were listed in the funding payload.

Why This Matters for Acquisition Watchers

Triastek sits at the intersection of 3D printing and pharmaceutical manufacturing, with a regulatory moat in China and multiple FDA IND clearances. The Series C+ round, led by a strategic investor like Johnson & Johnson Innovation – JJDC, signals continued confidence in the company's platform and its oral peptide strategy. For those tracking acquisition targets in drug delivery and manufacturing technology, Triastek's proprietary MED and 3DuS-OM platforms, combined with its production license and clinical pipeline, make it a notable player.

The company's Shanghai center adds capacity for clinical and global commercialization, which could support partnership or acquisition discussions with larger pharma players seeking differentiated oral drug delivery capabilities.

Key Facts

• Company: Triastek
• Headquarters: Nanjing, China
• Sector: Pharmaceutical technology, 3D-printed pharmaceuticals
• Round: Series C+
• Funding date: October 9, 2026
• Lead investor: Johnson & Johnson Innovation – JJDC, Inc.
• Funding amount: Not disclosed
• Currency: CNY
• Platform: Melt Extrusion Deposition (MED)
• Strategic focus: Oral peptides via 3DuS-OM platform
• Regulatory: Only company in China with a production license for 3D-printed drugs; multiple FDA IND clearances
• Facilities: Shanghai international R&D and production center

Outlook

The Series C+ round provides Triastek with additional capital to advance its oral peptide programs and expand its Shanghai operations. With Johnson & Johnson Innovation – JJDC leading, the company gains a strategic partner with deep pharmaceutical expertise. As Triastek continues to develop its 3D-printed drug pipeline and pursue global commercialization, it remains a company to watch in the pharmaceutical technology and drug delivery space.